These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 1622114

  • 21. Antitumor activity of a novel antiestrogen (Analog II) on human breast cancer cells.
    Jain PT, Rajah TT, Pento JT.
    Anticancer Drugs; 1997 Nov; 8(10):964-73. PubMed ID: 9436640
    [Abstract] [Full Text] [Related]

  • 22. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse.
    Robinson SP, Jordan VC.
    Cancer Res; 1989 Apr 01; 49(7):1758-62. PubMed ID: 2522347
    [Abstract] [Full Text] [Related]

  • 23. [Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin].
    Gao HD, Sun JZ, Bi DS, Ma R.
    Ai Zheng; 2003 Apr 01; 22(4):376-9. PubMed ID: 12703992
    [Abstract] [Full Text] [Related]

  • 24. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA, Lippman ME, Katzenellenbogen BS.
    Cancer Res; 1984 Nov 01; 44(11):5038-45. PubMed ID: 6488162
    [Abstract] [Full Text] [Related]

  • 25. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity.
    Hawariah A, Stanslas J.
    Anticancer Res; 1998 Nov 01; 18(6A):4383-6. PubMed ID: 9891496
    [Abstract] [Full Text] [Related]

  • 26. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
    Liu X, Pisha E, Tonetti DA, Yao D, Li Y, Yao J, Burdette JE, Bolton JL.
    Chem Res Toxicol; 2003 Jul 01; 16(7):832-7. PubMed ID: 12870885
    [Abstract] [Full Text] [Related]

  • 27. [The inhibiting effect of genistein on the growth of human breast cancer cells in vitro].
    He FJ, Wang J, Niu JZ, Wang JF.
    Zhongguo Zhong Yao Za Zhi; 2002 Dec 01; 27(12):936-9. PubMed ID: 12776537
    [Abstract] [Full Text] [Related]

  • 28. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
    Osborne CK, Hobbs K, Clark GM.
    Cancer Res; 1985 Feb 01; 45(2):584-90. PubMed ID: 3967234
    [Abstract] [Full Text] [Related]

  • 29. Interleukin 1 alpha blocks estradiol-stimulated growth and down-regulates the estrogen receptor in MCF-7 breast cancer cells in vitro.
    Danforth DN, Sgagias MK.
    Cancer Res; 1991 Mar 01; 51(5):1488-93. PubMed ID: 1997187
    [Abstract] [Full Text] [Related]

  • 30. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ, Raney S.
    Cell Biol Int; 1998 Mar 01; 22(6):413-9. PubMed ID: 10328849
    [Abstract] [Full Text] [Related]

  • 31. Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13.
    Strobl JS, Peterson VA.
    J Pharmacol Exp Ther; 1992 Oct 01; 263(1):186-93. PubMed ID: 1403784
    [Abstract] [Full Text] [Related]

  • 32. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture.
    Osborne CK, Boldt DH, Estrada P.
    Cancer Res; 1984 Apr 01; 44(4):1433-9. PubMed ID: 6704960
    [Abstract] [Full Text] [Related]

  • 33. Comparative studies on the polyamine metabolism and DFMO treatment of MCF-7 and MDA-MB-231 breast cancer cell lines and xenografts.
    Kremmer T, Pälyi I, Daubner D, Boldizsár M, Vincze B, Paulik E, Sugár J, Pokorny E, Túry E.
    Anticancer Res; 1991 Apr 01; 11(5):1807-13. PubMed ID: 1768053
    [Abstract] [Full Text] [Related]

  • 34. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
    Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF.
    Cancer Res; 1984 Jan 01; 44(1):112-9. PubMed ID: 6537799
    [Abstract] [Full Text] [Related]

  • 35. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer.
    Toko T, Shibata J, Nukatsuka M, Yamada Y.
    Cancer Chemother Pharmacol; 1997 Jan 01; 39(5):390-8. PubMed ID: 9054952
    [Abstract] [Full Text] [Related]

  • 36. Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.
    Journe F, Chaboteaux C, Dumon JC, Leclercq G, Laurent G, Body JJ.
    Br J Cancer; 2004 Nov 01; 91(9):1703-10. PubMed ID: 15477866
    [Abstract] [Full Text] [Related]

  • 37. Inhibition of growth of estrogen receptor positive and estrogen receptor negative breast cancer cells in culture by AA-etherA, a stable 2-5A derivative.
    Latham KE, Cosenza S, Reichenbach NL, Mordechai E, Adelson ME, Kon N, Horvath SE, Charubala R, Mikhailov SN, Pfeiderer W, Suhadolnik RJ.
    Oncogene; 1996 Feb 15; 12(4):827-37. PubMed ID: 8632905
    [Abstract] [Full Text] [Related]

  • 38. Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms.
    Collins-Burow BM, Burow ME, Duong BN, McLachlan JA.
    Nutr Cancer; 2000 Feb 15; 38(2):229-44. PubMed ID: 11525602
    [Abstract] [Full Text] [Related]

  • 39. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D, Dardes R, Liu H, MacGregor-Schafer J, Zapf J, Jordan V.
    Endocrinology; 2001 Feb 15; 142(2):838-46. PubMed ID: 11159857
    [Abstract] [Full Text] [Related]

  • 40. Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines.
    Sica G, Iacopino F, Marini L, Robustelli della Cuna G.
    Clin Ther; 1992 Feb 15; 14 Suppl A():87-96. PubMed ID: 1535023
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.